

MolMed expands its pipeline by entering the CAR-T field having exercised the option right on San Raffaele Hospital CAR-CD44v6 project

Milan (Italy), 13 April 2015 – MolMed S.p.A. (MLM.MI) announces having exercised its option right for the purchase of the San Raffaele Hospital (OSR) immune-gene therapy project against cancer developed using the Chimeric Antigen Receptor CD44v6 (CAR-CD44v6) with potential application in several haematological and solid tumour indications. The CAR-CD44v6 is part of the CAR-T family: lymphocytes armed with chimeric receptors that have demonstrated high anti-tumour potential, also against tumours - above all haematological - which are particularly aggressive and resistant to traditional therapies.

The CAR-CD44v6 project, which has already been successfully tested in appropriate murine models, represents a product candidate with a particularly high therapeutic potential, as it specifically recognises variant 6 (v6) of the antigen CD44 (CD44v6), expressed by many haematological malignancies, including acute myeloid leukaemia and multiple myeloma - as well as by several epithelial tumours, including breast, colon, pancreatic, head-and-neck and lung carcinomas.

The CAR-CD44v6 project has been acquired on the basis of the agreement signed in 2001 between MolMed and OSR, with which the Company holds an option right for the exploitation of intellectual property generated by OSR research projects in the fields of gene and molecular therapy for oncology and AIDS.

Claudio Bordignon, Chairman of the Board and CEO of MolMed, commented: "*The acquisition of this project allows MolMed to significantly expand its product pipeline, and enter one of today's most promising fields of new anti-tumour strategies, i.e. the immune-gene therapy of cancer. The CAR-CD44v6 project will benefit not only from our extensive experience and know-how in the field of gene and cell therapy, but also from the conjugation with the suicide gene TK, becoming the first CAR-T product to integrate a control system already extensively tested and validated in clinical trials*".

Please also note that the acquisition results in a transaction with related parties, since OSR owns the 100% of the share capital of Science Park Raf S.p.A. winding-up which in its turn owns, based on the information available as at 9th April, 2015, 1.48% of MolMed's share capital; moreover, by virtue of a shareholders' agreement terminated in March 2015, two members of MolMed's Board of Directors (which will expire upon approval of the annual report at December 2015), which were candidated in the list submitted by the parties to the shareholders' agreement, were appointed by Science Park Raf S.p.A. winding-up

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
info@molmed.com - www.molmed.com

Share capital € 11,019,314.98 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

For further information:

Marina Del Bue

**General Manager Corporate Governance & Administration
Investor Relations Director *ad int.***

MolMed S.p.A.

phone: +39 02 21277.411

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali srl

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@secp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.